Inari Medical Quarterly Income Statements Chart
Quarterly
|
Annual
Inari Medical Quarterly Income Statements Table
Quarterly
|
Annual
| Unit: USD | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| revenue | 153,390,000 | 145,820,000 | 143,194,000 | 132,094,000 | 126,366,000 | 119,005,000 | 116,167,000 | 107,771,000 | 96,204,000 | 92,744,000 | 86,752,000 | 83,218,000 | 72,916,000 | 63,453,000 | 57,397,000 | 48,611,000 | 38,715,000 | 25,392,000 |
| yoy | 21.39% | 22.53% | 23.27% | 22.57% | 31.35% | 28.32% | 33.91% | 29.50% | 31.94% | 46.16% | 51.14% | 71.19% | 88.34% | 149.89% | ||||
| qoq | 5.19% | 1.83% | 8.40% | 4.53% | 6.19% | 2.44% | 7.79% | 12.02% | 3.73% | 6.91% | 4.25% | 14.13% | 14.91% | 10.55% | 18.07% | 25.56% | 52.47% | |
| cost of goods sold | 19,846,000 | 19,993,000 | 18,893,000 | 17,006,000 | 14,477,000 | 13,844,000 | 13,741,000 | 13,128,000 | 11,064,000 | 10,347,000 | 9,967,000 | 8,280,000 | 7,040,000 | 4,814,000 | 4,623,000 | 3,686,000 | 3,228,000 | 3,487,000 |
| gross profit | 133,544,000 | 125,827,000 | 124,301,000 | 115,088,000 | 111,889,000 | 105,161,000 | 102,426,000 | 94,643,000 | 85,140,000 | 82,397,000 | 76,785,000 | 74,938,000 | 65,876,000 | 58,639,000 | 52,774,000 | 44,925,000 | 35,487,000 | 21,905,000 |
| yoy | 19.35% | 19.65% | 21.36% | 21.60% | 31.42% | 27.63% | 33.39% | 26.30% | 29.24% | 40.52% | 45.50% | 66.81% | 85.63% | 167.70% | ||||
| qoq | 6.13% | 1.23% | 8.01% | 2.86% | 6.40% | 2.67% | 8.22% | 11.16% | 3.33% | 7.31% | 2.46% | 13.76% | 12.34% | 11.11% | 17.47% | 26.60% | 62.00% | |
| gross margin % | 87.06% | 86.29% | 86.81% | 87.13% | 88.54% | 88.37% | 88.17% | 87.82% | 88.50% | 88.84% | 88.51% | 90.05% | 90.35% | 92.41% | 91.95% | 92.42% | 91.66% | 86.27% |
| operating expenses | ||||||||||||||||||
| research and development | 29,431,000 | 24,905,000 | 26,880,000 | 22,892,000 | 21,492,000 | 21,085,000 | 22,064,000 | 20,412,000 | 19,105,000 | 18,569,000 | 16,135,000 | 18,726,000 | 12,499,000 | 11,630,000 | 8,163,000 | 6,536,000 | 5,217,000 | 3,628,000 |
| selling, general and administrative | 108,271,000 | 114,153,000 | 103,055,000 | 101,493,000 | 88,284,000 | 85,586,000 | 85,700,000 | 80,122,000 | 75,833,000 | 73,156,000 | 63,732,000 | 54,466,000 | 56,104,000 | 42,897,000 | 36,898,000 | 31,393,000 | 23,080,000 | 18,880,000 |
| change in fair value of contingent consideration | 6,578,000 | 5,728,000 | 6,303,000 | |||||||||||||||
| amortization of intangible asset | 2,504,000 | 2,449,000 | 2,461,000 | |||||||||||||||
| acquisition-related expenses | 328,000 | 1,036,000 | 2,779,000 | |||||||||||||||
| total operating expenses | 147,112,000 | 148,271,000 | 141,478,000 | 124,385,000 | 109,776,000 | 106,671,000 | 107,764,000 | 100,534,000 | 94,938,000 | 91,725,000 | 79,867,000 | 73,192,000 | 68,603,000 | 54,527,000 | 45,061,000 | 37,929,000 | 28,297,000 | 22,508,000 |
| income from operations | -13,568,000 | -22,444,000 | -17,177,000 | -9,297,000 | 2,113,000 | -1,510,000 | -5,338,000 | -5,891,000 | -9,798,000 | -9,328,000 | -3,082,000 | 1,746,000 | -2,727,000 | 4,112,000 | 7,713,000 | 6,996,000 | 7,190,000 | -603,000 |
| yoy | -742.12% | 1386.36% | 221.79% | 57.82% | -121.57% | -83.81% | 73.20% | -437.40% | 259.30% | -326.85% | -139.96% | -75.04% | -137.93% | -781.92% | ||||
| qoq | -39.55% | 30.66% | 84.76% | -539.99% | -239.93% | -71.71% | -9.39% | -39.88% | 5.04% | 202.66% | -276.52% | -164.03% | -166.32% | -46.69% | 10.25% | -2.70% | -1292.37% | |
| operating margin % | -8.85% | -15.39% | -12.00% | -7.04% | 1.67% | -1.27% | -4.60% | -5.47% | -10.18% | -10.06% | -3.55% | 2.10% | -3.74% | 6.48% | 13.44% | 14.39% | 18.57% | -2.37% |
| other income | -130,000 | 23,000 | -23,000 | 3,478,000 | -682,000 | 26,000 | 39,000 | 187,000 | -59,000 | 252,000 | -14,000 | 30,000 | 7,000 | |||||
| interest income | 1,104,000 | 1,076,000 | 1,191,000 | 2,714,000 | 4,202,000 | 4,552,000 | 4,145,000 | 970,000 | 618,000 | 214,000 | 50,000 | 24,000 | 27,000 | 35,000 | 68,000 | 75,000 | 208,000 | 146,000 |
| interest expense | -78,000 | -77,000 | -78,000 | -69,000 | -43,000 | -44,000 | -40,000 | -74,000 | -74,000 | -73,000 | -73,000 | -75,000 | -73,000 | -74,000 | -73,000 | -75,000 | -251,000 | -463,000 |
| total other income | 896,000 | 1,022,000 | 1,090,000 | 6,123,000 | 3,477,000 | 4,534,000 | 4,144,000 | 1,083,000 | 485,000 | 393,000 | ||||||||
| income before income taxes | -12,672,000 | -21,422,000 | -16,087,000 | -3,174,000 | 5,590,000 | 3,024,000 | -1,194,000 | -4,808,000 | -9,313,000 | -8,935,000 | -3,129,000 | 1,681,000 | -2,743,000 | 4,080,000 | 7,667,000 | |||
| benefit from income taxes | 5,695,000 | 9,926,000 | 8,115,000 | 1,491,000 | 2,428,000 | 939,000 | 1,024,000 | 990,000 | 840,000 | 1,252,000 | 574,000 | 61,000 | 12,000 | 198,000 | ||||
| net income | -18,367,000 | -31,348,000 | -24,202,000 | -4,665,000 | 3,162,000 | 2,085,000 | -2,218,000 | -5,798,000 | -10,153,000 | -10,187,000 | -3,129,000 | 1,107,000 | -2,804,000 | 4,068,000 | 7,469,000 | |||
| yoy | -680.87% | -1603.50% | 991.16% | -19.54% | -131.14% | -120.47% | -29.11% | -623.76% | 262.09% | -350.42% | -141.89% | |||||||
| qoq | -41.41% | 29.53% | 418.80% | -247.53% | 51.65% | -194.00% | -61.75% | -42.89% | -0.33% | 225.57% | -382.66% | -139.48% | -168.93% | -45.53% | ||||
| net income margin % | -11.97% | -21.50% | -16.90% | -3.53% | 2.50% | 1.75% | -1.91% | -5.38% | -10.55% | -10.98% | -3.61% | 1.33% | -3.85% | 6.41% | 13.01% | 0% | 0% | 0% |
| other comprehensive income | ||||||||||||||||||
| foreign currency translation adjustments | 13,918,000 | -2,359,000 | -7,359,000 | 10,002,000 | -68,000 | -79,000 | 9,000 | 222,000 | -406,000 | -291,000 | -117,000 | -110,000 | -146,000 | 57,000 | -180,000 | |||
| unrealized gain on available-for-sale debt securities | 64,000 | 41,000 | 91,000 | 1,572,000 | 644,000 | -125,000 | -248,000 | |||||||||||
| total other comprehensive income | 13,982,000 | 10,043,000 | 23,000 | 1,794,000 | 238,000 | -416,000 | 51,000 | -162,000 | ||||||||||
| comprehensive income | -4,385,000 | -33,707,000 | 5,378,000 | 3,185,000 | 911,000 | -4,004,000 | -9,915,000 | -10,603,000 | -3,494,000 | 951,000 | -2,943,000 | 4,119,000 | 7,307,000 | |||||
| net income per share | ||||||||||||||||||
| basic | -0.31 | -0.54 | -0.42 | -0.08 | 0.06 | 0.04 | -0.04 | -0.1 | -0.19 | -0.19 | -0.06 | 0.02 | -0.06 | 0.08 | 0.15 | 0.17 | 0.13 | -0.16 |
| diluted | -0.31 | -0.54 | -0.42 | -0.08 | 0.05 | 0.04 | -0.04 | -0.1 | -0.19 | -0.19 | -0.06 | 0.02 | -0.06 | 0.07 | 0.13 | 0.13 | 0.12 | -0.16 |
| weighted-average common shares used to compute net income per share | ||||||||||||||||||
| basic | 58,366,364 | 58,142,454 | 57,938,115 | 56,770,657 | 57,384,884 | 57,207,902 | 54,756,024 | 52,837,674 | 53,491,625 | 53,183,767 | 50,954,715 | 49,815,914 | 50,001,996 | 49,669,652 | 49,355,945 | 32,033,827 | 48,335,443 | 24,295,900 |
| diluted | 58,366,364 | 58,142,454 | 57,938,115 | 56,770,657 | 58,588,452 | 58,496,350 | 54,756,024 | 52,837,674 | 53,491,625 | 53,183,767 | 50,954,715 | 55,594,159 | 50,001,996 | 55,595,016 | 55,722,293 | 51,554,996 | 55,355,846 | 24,295,900 |
| unrealized loss on available-for-sale debt securities | -4,000 | -1,095,000 | -865,000 | |||||||||||||||
| total other comprehensive loss | -2,359,000 | -7,363,000 | -1,174,000 | -856,000 | -365,000 | -62,500 | -139,000 | |||||||||||
| comprehensive loss | -31,565,000 | -3,074,000 | ||||||||||||||||
| other incomes | -24,000 | -41,000 | -11,000 | -651,000 | ||||||||||||||
| total other incomes | -47,000 | -65,000 | -16,000 | -32,000 | -46,000 | -11,000 | -694,000 | -3,201,000 | ||||||||||
| change in fair value of warrant liabilities | -2,884,000 | |||||||||||||||||
| unrealized gain on available-for-sale securities | -46,000 | 7,000 | -6,000 | 18,000 | ||||||||||||||
| net income and comprehensive income | 1,701,000 | 6,496,000 | -3,804,000 | |||||||||||||||
| weighted-average common shares used to compute net income per share, | ||||||||||||||||||
| basic | 58,366,364 | 58,142,454 | 57,938,115 | 56,770,657 | 57,384,884 | 57,207,902 | 54,756,024 | 52,837,674 | 53,491,625 | 53,183,767 | 50,954,715 | 49,815,914 | 50,001,996 | 49,669,652 | 49,355,945 | 32,033,827 | 48,335,443 | 24,295,900 |
| diluted | 58,366,364 | 58,142,454 | 57,938,115 | 56,770,657 | 58,588,452 | 58,496,350 | 54,756,024 | 52,837,674 | 53,491,625 | 53,183,767 | 50,954,715 | 55,594,159 | 50,001,996 | 55,595,016 | 55,722,293 | 51,554,996 | 55,355,846 | 24,295,900 |
We provide you with 20 years income statements for Inari Medical stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Inari Medical stock. Explore the full financial landscape of Inari Medical stock with our expertly curated income statements.
The information provided in this report about Inari Medical stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.